Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.68 |
| ▸ | SLC16A3 | O15427 | 5/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981049 | 0.84 | METAP2 (0.60) | METAP2MCL1TSHR | |
| SCHEMBL3983978 | 0.84 | METAP2 (0.73) | METAP2ALDH1A1MCL1TSHRMEN1 | |
| SCHEMBL3981500 | 0.83 | METAP2 (0.71) | METAP2ALDH1A1MCL1TSHRMEN1 | |
| SCHEMBL3986786 | 0.83 | METAP2 (0.71) | METAP2ALDH1A1MCL1TSHRMEN1 | |
| SCHEMBL3980969 | 0.83 | METAP2 (0.71) | METAP2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3982318 | 0.82 | METAP2 (0.60) | METAP2SLC16A3KCNA5ALDH1A1TSHR | |
| SCHEMBL3985574 | 0.82 | METAP2 (0.60) | METAP2SLC16A3KCNA5ALDH1A1HTT | |
| SCHEMBL3979192 | 0.81 | METAP2 (0.65) | METAP2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3979169 | 0.81 | METAP2 (1.00) | METAP2ALDH1A1MCL1TSHRMEN1 | |
| SCHEMBL6181264 | 0.81 | ALDH1A1 (0.62) | SLC16A3KCNA5ALDH1A1HTTPFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885SLC16A3 929/4885KCNA5 3408/4885 |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885SLC16A3 929/4885KCNA5 3408/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885SLC16A3 929/4885KCNA5 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.